Jiangzhi Ligan Decoction Inhibits GSDMD-Mediated Canonical/Noncanonical Pyroptosis Pathways and Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease
Open Access
- 18 June 2021
- journal article
- research article
- Published by Wiley in Disease Markers
- Vol. 2021, 1-11
Abstract
Increasing evidence suggests that gasdermin D (GSDMD) mediated pyroptosis signaling pathways play a vital role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Jiangzhi Ligan Decoction (JZLGD) has been verified to prevent NAFLD, but its specific mechanism has not been determined. In this study, an NAFLD model was established in Sprague-Dawley rats by a high-fat diet (HFD). After 12 weeks, JZLGD was orally administered once a day for 6 additional weeks. We investigated the effects of JZLGD on NAFLD rats and determined the GSDMD pathway-associated proteins to explore whether such effects were associated with pyroptosis. Our data show that JZLGD significantly reduced the liver index; improved serum lipid levels, liver function parameters, and lipid droplet content; and relieved NAFLD. We further found that the serum levels of the proinflammatory factors interleukin-1β (IL-1β), IL-18, tumor necrosis factor-α, and IL-6 were obviously decreased in the JZLGD group. HFD rats treated with GSDMD exhibited NLRP3, caspase-1, lipopolysaccharide (LPS), and caspase-11 activation; however, these effects were blunted by JZLGD treatment. Taken together, JZLGD may exert hepatoprotective effects against NAFLD in a rat HFD model by regulating GSDMD-mediated canonical/noncanonical pyroptosis pathways.Keywords
Funding Information
- Hunan University of Chinese Medicine (06, 18B252, 18B244)
- Scientific Research Fund of Hunan Provincial Education Department (06, 18B252, 18B244)
This publication has 39 references indexed in Scilit:
- Minocycline alleviates NLRP3 inflammasome-dependent pyroptosis in monosodium glutamate-induced depressive ratsBiochemical and Biophysical Research Communications, 2020
- Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and miceJournal of Hepatology, 2018
- Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessmentJournal of Gastroenterology and Hepatology, 2017
- Pore formation by GSDMD is the effector mechanism of pyroptosisThe EMBO Journal, 2016
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint WorkshopHepatology, 2014
- Pathogenesis and therapeutic approaches for non-alcoholic fatty liver diseaseWorld Journal of Hepatology, 2014
- Role of cytokines and chemokines in non-alcoholic fatty liver diseaseWorld Journal of Gastroenterology, 2012
- Epidemiology of Non-Alcoholic Fatty Liver DiseaseDigestive Diseases, 2010
- Insulin resistance, inflammation, and non-alcoholic fatty liver diseaseTrends in Endocrinology & Metabolism, 2008
- Non-alcoholic fatty liver disease: The mist gradually clearsJournal of Hepatology, 2008